The surrogate role of CDKN2A is not clear, and the reported rate of MTAP loss in our cohort was low; the detection method for MTAP loss has not yet validated by comparative genomic hybridization for pancreatic cancer in our NGS testing panel. Here, CDKN2A is linked to pancreatic neoplasm.